Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

P53 suppresses expression of the 14-3-3gamma oncogene

Authors: Vijayababu M Radhakrishnan, Charles W Putnam, Wenqing Qi, Jesse D Martinez

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

14-3-3 proteins are a family of highly conserved proteins that are involved in a wide range of cellular processes. Recent evidence indicates that some of these proteins have oncogenic activity and that they may promote tumorigenesis. We previously showed that one of the 14-3-3 family members, 14-3-3gamma, is over expressed in human lung cancers and that it can induce transformation of rodent cells in vitro.

Methods

qRTPCR and Western blot analysis were performed to examine 14-3-3gamma expression in non-small cell lung cancers (NSCLC). Gene copy number was analyzed by qPCR. P53 mutations were detected by direct sequencing and also by western blot. CHIP and yeast one hybrid assays were used to detect p53 binding to 14-3-3gamma promoter.

Results

Quantitative rtPCR results showed that the expression level of 14-3-3gamma was elevated in the majority of NSCLC that we examined which was also consistent with protein expression. Further analysis of the expression pattern of 14-3-3gamma in lung tumors showed a correlation with p53 mutations suggesting that p53 might suppress 14-3-3 gamma expression. Analysis of the gamma promoter sequence revealed the presence of a p53 consensus binding motif and in vitro assays demonstrated that wild-type p53 bound to this motif when activated by ionizing radiation. Deletion of the p53 binding motif eliminated p53's ability to suppress 14-3-3gamma expression.

Conclusion

Increased expression of 14-3-3gamma in lung cancer coincides with loss of functional p53. Hence, we propose that 14-3-3gamma's oncogenic activities cooperate with loss of p53 to promote lung tumorigenesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Muslin AJ, Tanner JW, Allen PM, Shaw AS: Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996, 84 (6): 889-97. 10.1016/S0092-8674(00)81067-3.CrossRefPubMed Muslin AJ, Tanner JW, Allen PM, Shaw AS: Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996, 84 (6): 889-97. 10.1016/S0092-8674(00)81067-3.CrossRefPubMed
2.
go back to reference Fu H, Subramanian RR, Masters SC: 14-3-3 proteins: structure, function, and regulation. Annual review of pharmacology and toxicology. 2000, 40: 617-47. 10.1146/annurev.pharmtox.40.1.617.CrossRefPubMed Fu H, Subramanian RR, Masters SC: 14-3-3 proteins: structure, function, and regulation. Annual review of pharmacology and toxicology. 2000, 40: 617-47. 10.1146/annurev.pharmtox.40.1.617.CrossRefPubMed
3.
go back to reference Hermeking H, Lengauer C, Polyak K, et al: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Molecular cell. 1997, 1 (1): 3-11. 10.1016/S1097-2765(00)80002-7.CrossRefPubMed Hermeking H, Lengauer C, Polyak K, et al: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Molecular cell. 1997, 1 (1): 3-11. 10.1016/S1097-2765(00)80002-7.CrossRefPubMed
4.
go back to reference Porter GW, Khuri FR, Fu H: Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Seminars in cancer biology. 2006, 16 (3): 193-202. 10.1016/j.semcancer.2006.03.003.CrossRefPubMed Porter GW, Khuri FR, Fu H: Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Seminars in cancer biology. 2006, 16 (3): 193-202. 10.1016/j.semcancer.2006.03.003.CrossRefPubMed
5.
go back to reference Thorson JA, Yu LW, Hsu AL, et al: 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Molecular and cellular biology. 1998, 18 (9): 5229-38.CrossRefPubMedPubMedCentral Thorson JA, Yu LW, Hsu AL, et al: 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Molecular and cellular biology. 1998, 18 (9): 5229-38.CrossRefPubMedPubMedCentral
6.
go back to reference Ichimura T, Isobe T, Okuyama T, Yamauchi T, Fujisawa H: Brain 14-3-3 protein is an activator protein that activates tryptophan 5-monooxygenase and tyrosine 3-monooxygenase in the presence of Ca2+, calmodulin-dependent protein kinase II. FEBS letters. 1987, 219 (1): 79-82. 10.1016/0014-5793(87)81194-8.CrossRefPubMed Ichimura T, Isobe T, Okuyama T, Yamauchi T, Fujisawa H: Brain 14-3-3 protein is an activator protein that activates tryptophan 5-monooxygenase and tyrosine 3-monooxygenase in the presence of Ca2+, calmodulin-dependent protein kinase II. FEBS letters. 1987, 219 (1): 79-82. 10.1016/0014-5793(87)81194-8.CrossRefPubMed
7.
go back to reference Berg D, Holzmann C, Riess O: 14-3-3 proteins in the nervous system. Nature reviews. 2003, 4 (9): 752-62. 10.1038/nrn1197.CrossRefPubMed Berg D, Holzmann C, Riess O: 14-3-3 proteins in the nervous system. Nature reviews. 2003, 4 (9): 752-62. 10.1038/nrn1197.CrossRefPubMed
8.
go back to reference Qi W, Liu X, Qiao D, Martinez JD: Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. International journal of cancer. 2005, 113 (3): 359-63. 10.1002/ijc.20492.CrossRefPubMed Qi W, Liu X, Qiao D, Martinez JD: Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. International journal of cancer. 2005, 113 (3): 359-63. 10.1002/ijc.20492.CrossRefPubMed
9.
go back to reference Cheng L, Pan CX, Zhang JT, et al: Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res. 2004, 10 (9): 3064-8. 10.1158/1078-0432.CCR-03-0652.CrossRefPubMed Cheng L, Pan CX, Zhang JT, et al: Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res. 2004, 10 (9): 3064-8. 10.1158/1078-0432.CCR-03-0652.CrossRefPubMed
10.
go back to reference Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene. 2001, 20 (26): 3348-53. 10.1038/sj.onc.1204438.CrossRefPubMed Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene. 2001, 20 (26): 3348-53. 10.1038/sj.onc.1204438.CrossRefPubMed
11.
go back to reference Matta A, Bahadur S, Duggal R, Gupta SD, Ralhan R: Over-expression of 14-3-3zeta is an early event in oral cancer. BMC cancer. 2007, 7: 169-10.1186/1471-2407-7-169.CrossRefPubMedPubMedCentral Matta A, Bahadur S, Duggal R, Gupta SD, Ralhan R: Over-expression of 14-3-3zeta is an early event in oral cancer. BMC cancer. 2007, 7: 169-10.1186/1471-2407-7-169.CrossRefPubMedPubMedCentral
12.
go back to reference Akahira J, Sugihashi Y, Suzuki T, et al: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res. 2004, 10 (8): 2687-93. 10.1158/1078-0432.CCR-03-0510.CrossRefPubMed Akahira J, Sugihashi Y, Suzuki T, et al: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res. 2004, 10 (8): 2687-93. 10.1158/1078-0432.CCR-03-0510.CrossRefPubMed
13.
go back to reference Guweidhi A, Kleeff J, Giese N, et al: Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis. 2004, 25 (9): 1575-85. 10.1093/carcin/bgh159.CrossRefPubMed Guweidhi A, Kleeff J, Giese N, et al: Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis. 2004, 25 (9): 1575-85. 10.1093/carcin/bgh159.CrossRefPubMed
14.
go back to reference Okada T, Masuda N, Fukai Y, et al: Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas. Anticancer research. 2006, 26 (4B): 3105-10.PubMed Okada T, Masuda N, Fukai Y, et al: Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas. Anticancer research. 2006, 26 (4B): 3105-10.PubMed
15.
go back to reference Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999, 401 (6753): 616-20. 10.1038/44188.CrossRefPubMed Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999, 401 (6753): 616-20. 10.1038/44188.CrossRefPubMed
16.
go back to reference Urano T, Saito T, Tsukui T, et al: Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002, 417 (6891): 871-5. 10.1038/nature00826.CrossRefPubMed Urano T, Saito T, Tsukui T, et al: Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002, 417 (6891): 871-5. 10.1038/nature00826.CrossRefPubMed
17.
go back to reference Dellambra E, Golisano O, Bondanza S, et al: Downregulation of 14-3-3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. The Journal of cell biology. 2000, 149 (5): 1117-30. 10.1083/jcb.149.5.1117.CrossRefPubMedPubMedCentral Dellambra E, Golisano O, Bondanza S, et al: Downregulation of 14-3-3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. The Journal of cell biology. 2000, 149 (5): 1117-30. 10.1083/jcb.149.5.1117.CrossRefPubMedPubMedCentral
18.
go back to reference Jin YH, Kim YJ, Kim DW, et al: Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochemical and biophysical research communications. 2008, 368 (3): 690-5. 10.1016/j.bbrc.2008.01.114.CrossRefPubMed Jin YH, Kim YJ, Kim DW, et al: Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochemical and biophysical research communications. 2008, 368 (3): 690-5. 10.1016/j.bbrc.2008.01.114.CrossRefPubMed
19.
go back to reference Qi W, Liu X, Chen W, Li Q, Martinez JD: Overexpression of 14-3-3gamma causes polyploidization in H322 lung cancer cells. Molecular carcinogenesis. 2007, 46 (10): 847-56. 10.1002/mc.20314.CrossRefPubMed Qi W, Liu X, Chen W, Li Q, Martinez JD: Overexpression of 14-3-3gamma causes polyploidization in H322 lung cancer cells. Molecular carcinogenesis. 2007, 46 (10): 847-56. 10.1002/mc.20314.CrossRefPubMed
20.
go back to reference Carney DN: Oncogenes and genetic abnormalities in lung cancer. Chest. 1989, 96 (1 Suppl): 25S-7S. 10.1378/chest.96.1_Supplement.25S.CrossRefPubMed Carney DN: Oncogenes and genetic abnormalities in lung cancer. Chest. 1989, 96 (1 Suppl): 25S-7S. 10.1378/chest.96.1_Supplement.25S.CrossRefPubMed
21.
go back to reference Massion PP, Kuo WL, Stokoe D, et al: Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer research. 2002, 62 (13): 3636-40.PubMed Massion PP, Kuo WL, Stokoe D, et al: Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer research. 2002, 62 (13): 3636-40.PubMed
22.
go back to reference Kuo MH, Allis CD: In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment. Methods (San Diego, Calif. 1999, 19 (3): 425-33.CrossRef Kuo MH, Allis CD: In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment. Methods (San Diego, Calif. 1999, 19 (3): 425-33.CrossRef
23.
go back to reference Radhakrishnan VM, Martinez JD: 14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PloS one. 5 (7): e11433- Radhakrishnan VM, Martinez JD: 14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PloS one. 5 (7): e11433-
24.
go back to reference Fu L, Benchimol S: Participation of the human p53 3'UTR in translational repression and activation following gamma-irradiation. The EMBO journal. 1997, 16 (13): 4117-25. 10.1093/emboj/16.13.4117.CrossRefPubMedPubMedCentral Fu L, Benchimol S: Participation of the human p53 3'UTR in translational repression and activation following gamma-irradiation. The EMBO journal. 1997, 16 (13): 4117-25. 10.1093/emboj/16.13.4117.CrossRefPubMedPubMedCentral
25.
go back to reference Riley T, Sontag E, Chen P, Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008, 9 (5): 402-12. 10.1038/nrm2395.CrossRefPubMed Riley T, Sontag E, Chen P, Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008, 9 (5): 402-12. 10.1038/nrm2395.CrossRefPubMed
Metadata
Title
P53 suppresses expression of the 14-3-3gamma oncogene
Authors
Vijayababu M Radhakrishnan
Charles W Putnam
Wenqing Qi
Jesse D Martinez
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-378

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine